{"entity":{"id":"jinling-cohort","kind":"trial","name":"Jinling Cohort (MERCURY multi-omic test in Nanjing)","aka":["Jinling Cohort","MERCURY"],"tldr":"A Chinese cohort of 15,000 people at average risk followed with a multi-omic blood test for several cancers.","summary":"Jinling Cohort (NCT06011694) is an observational study sponsored by Nanjing Shihejiyin Technology, Inc. It is a prospective cohort study of the multi-omic liquid biopsy MCED test MERCURY in an average-risk Chinese population.\n\nThe registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 15,000 participants, a start on 15 June 2022 and primary completion expected on 15 May 2027.","status":"recruiting","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT06011694","url":"https://clinicaltrials.gov/study/NCT06011694"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06011694","phase":"observational","setting":"Adults aged 45 to 75 at average risk in Nanjing, China, followed with the MERCURY multi-omic blood test and annual check-ups","sponsor":"Nanjing Shihejiyin Technology, Inc.","started":"2022-06-15","startedType":"actual","enrolled":15000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/jinling-cohort/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}]}}